Sumatriptan Tablet
Product Images NDC 68071-3755

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 68071-3755). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3755 9)

This is a medication label for Sumatriptan 100mg tablets. It contains a warning to keep out of reach of children and provides details about the ingredients, dosage, lot numbers, manufacturer information, and how to report side effects. It also includes an expiration date, storage instructions, and a contact number for medical advice and reporting side effects to the FDA. It is important to follow the instructions and consult a doctor for any concerns.*

FDA Label Image

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)

FDA Label Image

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Poo (Sumatriptan Fig2)

Estimated Probability of Remedication or Rescue: 100% 4% 1% * placebo 4 25mg 50 mg 100 mg 0 1 Time to Hours From Initial Dose:*

FDA Label Image

Chemical Structure (Sumatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.